These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22964596)

  • 21. Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring.
    Goldsmith YB; Liu J; Chou J; Hoffman J; Comenzo RL; Steingart RM
    Am J Cardiol; 2009 Oct; 104(7):990-4. PubMed ID: 19766769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predisposing factors and consequences of elevated biomarker levels in long-distance runners aged >or=55 years.
    Sahlén A; Gustafsson TP; Svensson JE; Marklund T; Winter R; Linde C; Braunschweig F
    Am J Cardiol; 2009 Nov; 104(10):1434-40. PubMed ID: 19892064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation.
    Leung N; Dispenzieri A; Lacy MQ; Kumar SK; Hayman SR; Fervenza FC; Cha SS; Gertz MA
    Clin J Am Soc Nephrol; 2007 May; 2(3):440-4. PubMed ID: 17699449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of a highly sensitive assay for cardiac troponin T and N-terminal pro-brain natriuretic peptide to diagnose acute rejection in pediatric cardiac transplant recipients.
    Dyer AK; Barnes AP; Fixler DE; Shah TK; Sutcliffe DL; Hashim I; Drazner MH; de Lemos JA
    Am Heart J; 2012 Apr; 163(4):595-600. PubMed ID: 22520525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System.
    Grogan M; Scott CG; Kyle RA; Zeldenrust SR; Gertz MA; Lin G; Klarich KW; Miller WL; Maleszewski JJ; Dispenzieri A
    J Am Coll Cardiol; 2016 Sep; 68(10):1014-20. PubMed ID: 27585505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-terminal B-type natriuretic peptide assessment provides incremental prognostic information in patients with acute coronary syndromes and normal troponin T values upon admission.
    Weber M; Bazzino O; Navarro Estrada JL; Fuselli JJ; Botto F; Perez de Arenaza D; Möllmann H; Nef HN; Elsässer A; Hamm CW
    J Am Coll Cardiol; 2008 Mar; 51(12):1188-95. PubMed ID: 18355657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
    Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
    Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation.
    Herrmann SM; Gertz MA; Stegall MD; Dispenzieri A; Cosio FC; Kumar S; Lacy MQ; Dean PG; Prieto M; Zeldenrust SR; Buadi FK; Russell SJ; Nyberg SL; Hayman SR; Dingli D; Fervenza FC; Leung N
    Nephrol Dial Transplant; 2011 Jun; 26(6):2032-6. PubMed ID: 21543655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.
    Dispenzieri A; Gertz MA; Kyle RA; Lacy MQ; Burritt MF; Therneau TM; McConnell JP; Litzow MR; Gastineau DA; Tefferi A; Inwards DJ; Micallef IN; Ansell SM; Porrata LF; Elliott MA; Hogan WJ; Rajkumar SV; Fonseca R; Greipp PR; Witzig TE; Lust JA; Zeldenrust SR; Snow DS; Hayman SR; McGregor CG; Jaffe AS
    Blood; 2004 Sep; 104(6):1881-7. PubMed ID: 15044258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant.
    Saba N; Sutton D; Ross H; Siu S; Crump R; Keating A; Stewart A
    Bone Marrow Transplant; 1999 Oct; 24(8):853-5. PubMed ID: 10516696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia.
    Anagnostopoulos A; Hari PN; Pérez WS; Ballen K; Bashey A; Bredeson CN; Freytes CO; Gale RP; Gertz MA; Gibson J; Goldschmidt H; Lazarus HM; McCarthy PL; Reece DE; Vesole DH; Giralt SA
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):845-54. PubMed ID: 16864055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
    Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
    Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Usefulness of N-terminal pro-brain natriuretic peptide to predict postoperative cardiac complications and long-term mortality after emergency lower limb orthopedic surgery.
    Chong CP; Ryan JE; van Gaal WJ; Lam QT; Sinnappu RN; Burrell LM; Savige J; Lim WK
    Am J Cardiol; 2010 Sep; 106(6):865-72. PubMed ID: 20816130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
    Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
    Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Admission N-terminal pro-brain natriuretic peptide and its interaction with admission troponin T and ST segment resolution for early risk stratification in ST elevation myocardial infarction.
    Björklund E; Jernberg T; Johanson P; Venge P; Dellborg M; Wallentin L; Lindahl B;
    Heart; 2006 Jun; 92(6):735-40. PubMed ID: 16251228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.
    Bergesio F; Ciciani AM; Manganaro M; Palladini G; Santostefano M; Brugnano R; Di Palma AM; Gallo M; Rosati A; Tosi PL; Salvadori M;
    Nephrol Dial Transplant; 2008 Mar; 23(3):941-51. PubMed ID: 17951308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy.
    James SK; Lindbäck J; Tilly J; Siegbahn A; Venge P; Armstrong P; Califf R; Simoons ML; Wallentin L; Lindahl B
    J Am Coll Cardiol; 2006 Sep; 48(6):1146-54. PubMed ID: 16978997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.
    Palladini G; Campana C; Klersy C; Balduini A; Vadacca G; Perfetti V; Perlini S; Obici L; Ascari E; d'Eril GM; Moratti R; Merlini G
    Circulation; 2003 May; 107(19):2440-5. PubMed ID: 12719281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of renal function and cardiac biomarkers (NT-proBNP and Troponin) in determining mortality and cardiac outcome in atheromatous renovascular disease.
    Chrysochou C; Manzoor S; Wright J; Roberts SA; Wood G; McDowell G; Kalra PA
    Kidney Blood Press Res; 2009; 32(5):373-9. PubMed ID: 19887825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N-terminal pro-brain natriuretic peptide, kidney disease and outcome in patients with chronic heart failure.
    Bruch C; Reinecke H; Stypmann J; Rothenburger M; Schmid C; Breithardt G; Wichter T; Gradaus R
    J Heart Lung Transplant; 2006 Sep; 25(9):1135-41. PubMed ID: 16962477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.